Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:33 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)
NCT02186821 · Novartis Pharmaceuticals · PHASE2 · terminated · last registry update 2021-04-08 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study was terminated due to low enrollment” | – | Registry record, Novartis Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ALK within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-02-18Also stopped (withdrawn): Sameek Roychowdhury, Brigatinib (NCT03868423)
- 2022-02-11Results posted on the registry: University of Colorado, Denver, Crizotinib (NCT03088930)
- 2022-02-09Results posted on the registry: Pfizer, Avelumab + PF-06463922 (NCT02584634)
- 2022-01-24Phase 3 first posted: Xuanzhu Biopharmaceutical Co., Ltd., XZP-3621 + Crizotinib (NCT05204628)
- 2021-12-27Phase 3 first posted: Hoffmann-La Roche, Alectinib + Entrectinib (NCT05170204)
- 2021-12-17Results posted on the registry: University of Texas Southwestern Medical Center, Ceritinib (NCT02513667)
- 2021-12-14Results posted on the registry: Takeda, Brigatinib (NCT03410108)
- 2021-10-26Results posted on the registry: Pfizer, Lorlatinib (NCT03909971)
- 2021-10-25Results posted on the registry: Ariad Pharmaceuticals, Brigatinib (NCT03535740)
- 2021-10-14Results posted on the registry: Pfizer, PF-02341066 + Rifampin (NCT00585195)
- 2021-09-27Also stopped (terminated): Dana-Farber Cancer Institute, Alectinib (NCT03131206)
- 2021-09-13Also stopped (terminated): M.D. Anderson Cancer Center, Crizotinib (Xalkori) + Pazopanib (NCT01548144)
- 2021-08-20Results posted on the registry: Ariad Pharmaceuticals, Brigatinib + Crizotinib (NCT02737501)
- 2021-06-30Results posted on the registry: University of Washington, Gene Expression Analysis + Genetic Variation Analysis (NCT02551718)
- 2021-06-09Results posted on the registry: Wake Forest University Health Sciences, Crizotinib (NCT02612194)
- 2021-05-06Results posted on the registry: Bristol-Myers Squibb, Nivolumab + Bevacizumab (NCT02574078)
- 2021-04-26Results posted on the registry: University of Oxford, PF-02341066 + PD-0325901 (NCT02510001)
- 2021-04-01Results posted on the registry: Pfizer, Lorlatinib + Crizotinib (NCT03052608)
- 2021-02-21Results posted on the registry: Pfizer, Lorlatinib (NCT03542305)
- 2021-01-05Also stopped (withdrawn): Fox Chase Cancer Center, Brigatinib (NCT03719898)
- 2020-12-24Results posted on the registry: Novartis Pharmaceuticals, LDK378 (NCT02450903)
- 2020-12-16Results posted on the registry: Novartis Pharmaceuticals, BYL719 + INC280 (NCT02276027)
- 2020-11-17Phase 3 first posted: Qilu Pharmaceutical Co., Ltd., WX-0593 Tablets + crizotinib (NCT04632758)
- 2020-11-06Results posted on the registry: National Cancer Institute (NCI), 75 approved agents (NCT02788201)
- 2020-10-27Phase 3 first posted: Hoffmann-La Roche, Entrectinib + Crizotinib (NCT04603807)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision